861453-16-9

Basic information

• Product Name: 4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzaMide
• Synonyms: 4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzaMide
• CAS NO: 861453-16-9
• Molecular Formula: C₁₅H₂₁N₃O₆
• Molecular Weight: 339.34374
• Mol File: 861453-16-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzaMide(861453-16-9)
• EPA Substance Registry System: 4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzaMide(861453-16-9)

Safety Data

• Hazardous Substances Data: 861453-16-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzaMide is used as a research compound for its potential anti-inflammatory and anti-cancer properties. Its structure and activity have been investigated to understand its potential biological effects, making it a valuable tool in the development of new drugs.
Used in Medicinal Chemistry:
4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzaMide has demonstrated potential as a building block for the synthesis of other compounds with medicinal applications. Its unique structure allows for further chemical modifications, enabling the creation of novel therapeutic agents with improved efficacy and selectivity.
Used in Drug Development:
4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzaMide is utilized in drug development as a lead compound for the discovery of new pharmaceuticals. Its promising biological properties and versatile chemical structure make it an attractive candidate for optimization and advancement through the drug development pipeline.

Upstream product

• 675126-26-8 2-nitro-4-methoxy-5-[3-(morpholin-4-yl)propoxy]benzonitrile 
• 675126-28-0 4-methoxy-3-[3-(morpholin-4-yl)propoxy]benzonitrile 
• 52805-46-6 2-methoxy-5-cyanophenol 
• 621-59-0 isovanillin 

Downstream Products

• 246512-44-7 2-amino-4-methoxy-5-[3-(morpholin-4-yl)propoxy]benzamide 

Relevant articles and documents

Preparing method of gefitinib intermediate

The invention discloses a preparing method of a gefitinib intermediate. The method includes the following steps of firstly, making a compound 1 react in the presence of sodium formate, formic acid andhydroxylamine sulphate to obtain a compound 2; secondly, making the compound 2 and a compound 3 react in the presence of potassium carbonate in a first solvent to obtain a compound 4; thirdly, makingthe compound 4 react in the presence of sulfuric acid and nitric acid in a second solvent to obtain a compound 5; fourthly, making the compound 5 react in the presence of alkaline and hydrogen peroxide in a third solvent to obtain a compound 6; fifthly, making the compound 6 react in the presence of ammonium formate and palladium/carbon in a fourth solvent to obtain a compound 7; sixthly, makingthe compound 7 react in the presence of formic acid and formamide to obtain a compound 8.

AN IMPROVED PROCESS FOR THE PREPARATION OF GEFITINIB

Present invention discloses an improved process for the preparation of gefitinib (4-(3'-chloro-4'-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline), of formula-I, which comprises: (i) etherification of iso-vanillin with 3-morpholinopropyl halide, (ii) nitration using nitric acid, (iii) oximation, (iv) dehydration, (v) reduction-cum-hydrolysis, (vi) quinazolinone formation, (vii) introduction of a leaving group at C-4 position in quinozolinone, and (viii) condensation with 3-chloro4-fluoroaniline to get the crude gefitinib. Purification of crude gefitinib is achieved via acid/base treatment or by crystallization from solvents such as ethyl acetate, isopropanol, acetonitrile, and methyl ethyl ketone. Formula I, IX, XI, XIII, XV and XVI.